Sources and prices for drug-resistant tuberculosis medicines
Author:
Organization: Médecins Sans Frontières (MSF) Access Campaign, The International Union Against Tuberculosis and Lung Disease
Year: November 2012
Document Type: Report
Abstract/Summary: This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.
Finally, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.
Disease/Therapeutic Area: Tuberculosis
Geography:
Income Classification (World Bank):
Market Shortcomings:
Focus Areas:
Interventions:
Keywords:
]]>